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several sources of real world data available to researchers.METHODS:We compare
and contrast the pros and cons of data available from administrative (payment)
databases, electronic medical record (EMR) databases, and surveys. RESULTS: Ad-
ministrative claims databases provide fully-integrated, all-encounter patient data
on diagnoses, procedures, and payments. However, data quality varies depending
upon whether particular fields are required for provider payment. Data on lab and
test values are typically lacking. Prescriptions that are written, but not filled by the
patient, are usually not captured. Medical record data overlap, to a certain extent,
with administrative data. While information on payments for services may not be
included, detailed information on test results and lab values are usually captured
in the EMR. Data are included on written prescriptions, but the researcher will not
know whether the prescription was filled by the patient. Depending upon the clin-
ical system covered, only some encounters (e.g., ambulatory care in the outpatient
setting) may be available. Both administrative and EMR data hold the potential to
provide longitudinal patient information that is not subject to recall or social de-
sirability biases that often affect survey data. However, information on satisfaction
with care, quality of life, activities of daily living, and many other metrics, may only
be captured with survey data. CONCLUSIONS: Several sources of rich, longitudinal
patient data are available to provide real world evidence on drug effectiveness and
cost. In some cases, data may be combined to overcome limitations of a single
source. With care, data may be found that will produce generalizable findings for
the population of interest.
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OBJECTIVES: Gathering data tends to be an expensive and time consuming task.
During the IFEDH research project different methods for using routine data on
models in HTA were discussed, improved and developed. Connecting a rich dataset
from Austrias inpatient sector lacking patient identifiers and (kind of) personalized
but sparse records from the outpatient sector provided by different social security
institutions is the objective of this project. A detailed description of the setup and
usage of the results were presented at the SHIP Conference 2011 in St. Andrews
(http://www.scot-ship.ac.uk/conference-2011) and the International Data Linkage
Conference 2012 in Perth (http://www.datalinkage2012.com.au/). METHODS: Doc-
umentation of prior processing and information of the provided data were not fully
available and also questionable data quality and the presence of possible dupli-
cates result in technical and contextual challenges. After prepossessing, data qual-
ity assessment and other preparations, a deterministic record linkage approach
was developed using a combination of the open and freely available statistical
environment R and PostgreSQL database. Based on dynamically created SQL state-
ments and extensive logging, the linkage process can be enhanced easily if new
knowledge about the input data gets available. RESULTS: The resulting linked
dataset provides high quality and immediately available information. Additionally
the deterministic linkage process can be examined and understood by its users.
Therefore linkage and data errors are identified easily and feedback can be used to
enhance the overall result. These experiences also lay the foundation for more
advanced linkage methods and further improvements. CONCLUSIONS: After the
long and challenging way from the first data import to a functioning data collec-
tion, adequate information can now be used in different projects with low costs
and users confidence.
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OBJECTIVES:With introduction of AMNOG legislation, the pharmaceutical compa-
nies must submit a dossier when launching new drugs. The dossier must include
an estimate of number of patients to be treated. This is particularly challenging in
case of rare diseases, as shown with transthyretin-type familial amyloid polyneu-
ropathy (TTR-FAP). METHODS: Several sources were used for a comprehensive
gathering of information. Apart from systematic literature research, incidence data
was searched by internet research and within patient registers. Since current ther-
apy of choice is liver transplantation, the German Organ Transplantation Founda-
tion was consulted regarding frequency of liver transplantation in connection with
TTR-FAP. Assuming all patients are immediately placed on a waiting list after
diagnosis, the number of annually performed surgeries was equaled with the inci-
dence of the TTR-FAP. Results of this research were compared to billing data of a
national statutory health insurance. RESULTS: Given its European prevalence of
approx. 1.1/100,000, TTR-FAP is an ultra-orphan-disease. For endemic regions
(Sweden, Portugal) the disease is well captured and documented. For Germany, no
comparable published data is available. 5 national treatment centers were identi-
fied that document their patients in various registers, reflecting an incidence of
about 7 surgeries per year. According to the German Organ Transplantation Foun-
dation on average 6 new TTR-FAP patients per annum were added to the waiting
list, confirming the estimate of the incidence derived from registers. Domino trans-
plantation is usual in TTR-FAP with an average of 6.5 domino transplantations p.a.,
validating the estimate of an incidence of 6 – 7 patients per year. Billing data reflects
an estimated prevalence between 0.6 and 1.4/100,000. CONCLUSIONS: Data on the
prevalence of rare diseases frequently is not available or very unreliable. Different
sources produce strongly varying results due to several reasons. This must be taken
into account when assessing the number of patients in the value dossiers for new
drugs.
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OBJECTIVES: PROQOLID was developed in 2002 to provide all those involved in
health care evaluation with a comprehensive and unique source of information on
Patient-Reported Outcome (PRO) and Health-Related Quality of Life (HRQL) mea-
sures available through the Internet. The objective of this study is to review the
evolution of content, structure, and functionalities of PROQOLID since 2002.
METHODS: The archives of PROQOLID were searched to retrieve the database just
before its launch and to compare its content and structure as it was in April 2012.
RESULTS: The first database, then known as QOLID, was retrieved. It included 313
instruments (32 generic and 281 disease- or condition-specific). Instruments spe-
cific to oncology were the most frequent (54). The structure had three categories:
contact, conditions of use, and a copy of the questionnaire. By comparison, the
April 2012 database includes 714 instruments (128% increase, with 100 generic and
614 specific), with an increase of almost 40 instruments each year (up by 401 in 10
1/2 years). Instruments specific to nervous system diseases are the most frequent
(141), reflecting the evolution in the field (e.g., 76.7% of the neurological products
authorized by the EMA have been approved since 2002). The information displayed
for each instrument has been improved with the addition of five categories: trans-
lations available, descriptive information, content validity documentation, mea-
surement properties, references, and websites. In January 2005 the database was
renamed PROQOLID to reflect the wider use of the term PRO. In April 2012, a new
Google-type search engine was added to make browsing more user friendly. Soon
all users will have more information about instruments distributed by MAPI Re-
search Trust. CONCLUSIONS: In just over 10 years, the PROQOLID database has
considerably evolved in content and structure, and offers a range of information
and services adapted to the evolution of the field.
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OBJECTIVES: As part of consulting projects IMSCG performs 5000 payer inter-
views p.a. Interview analysis is typically focused on insights directly related to
research objectives. However, often respondents provide perceptions/ un-
prompted insights unrelated to research objectives, which have never been anal-
ysed before. The objective was to test whether information obtained from un-
prompted payer responses in interview write-ups can be identified and analysed,
to develop insights of payer perceptions of pharma and their impact on payer
decisions. METHODS: We selected 100 projects performed 2008-2011 including
double blinded interviews with national/regional payers/advisors, recorded in Eng-
lish in the IMSCG project database. Interviews were screened for quotes reflecting
perceptions of pharma unrelated to the research objective. Only unprompted ex-
pressions were extracted and buzz-words created that allowed compression into a
single word/phrase. Buzz-words were valued and categorized into perception clus-
ters (reputation, interaction, employees, portfolio and research) to identify the
cause of perceptions. Quotes linking perceptions directly to decisions were
mapped separately. Respondents’ function and geography were interlinked with
the information. RESULTS: We identified 543 interviews including 900 quotes with
unprompted expressions of perceptions in 1900 buzz-words. Distribution of inter-
views was equal between national/regional payers, but 80% of quotes came from
regional payers. Top5 EU accounted for majority of quotes. Company specific and
industry perceptions were evenly split. Data allows a variety of perception analysis:
national vs. regional payer, pharma vs. company, company perceptions of national
vs. regional payers. Perception clusters identify the cause of perceptions. Analysis
of the impact of perception on payer decisions is feasible, based on 5% of overall
quotes. CONCLUSIONS: The data allows a structured analysis of unprompted ex-
pressions of payer perceptions in retrospective research. Database processing is
ongoing to derive in the future statistically significant answers related to the im-
pact of payer perceptions on decisions and what these perceptions are based upon.
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OBJECTIVES: Crohn’s disease is a chronic relapsing-remitting inflammatory bowel
disease with heterogeneous disease course, requiring life-long treatment. Pheno-
types explaining disease heterogeneity is of interest in optimizing allocation of
health care resources, e.g. to avoid expensive maintenance treatment to prolong
remission in patients who seldom relapse. To develop economic models for eval-
uation of treatments, our objective was to estimate parameters of a Markov chain
from data on disease activity and resource consumption and to improve model fit
by allowing different phenotypes. METHODS: We had individual data on relapse
and remission, surgery, use of medicines and other resources, aggregated over
three month periods, from inflammatory bowel disease patients from 1991 and ten
year onwards. Data from Crohn’s disease patients were extracted. An exact maxi-
mum likelihood estimator using observations aggregated over time was used to
estimate monthly transition probabilities. This estimator was adjusted to allow
different disease phenotypes using an Expectation-Maximization method which
identifies the phenotypes that best describe patient heterogeneity. The estimated
parameters were used to derive the mean durations of a relapse and a period of
remission to describe the phenotypes. RESULTS: At least two distinct phenotypes
were found in each country, seldom-relapsing (once/3 years) and often-relapsing
(once/3 years). The best fit was with four phenotypes in Denmark, three pheno-
types in the Netherlands and in Italy, and two in Norway, Israel, Ireland, Spain, and
Greece. In Denmark and Italy there was a single seldom-relapsing phenotype and
more than one often-relapsing phenotype. In Netherlands there was two seldom-
relapsing phenotypes. Denmark, The Netherlands, Israel, Ireland and Italy have
roughly as many seldom-relapsing as often-relapsing patients. Norway, Spain and
Greece have a majority of seldom-relapsing patients. CONCLUSIONS: Allowing for
different phenotypes improves model fit. Health care resource allocation can be
optimized using phenotypes. Using data aggregated over time appears to remain a
challenge.
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OBJECTIVES: The Swedish National Diabetes Register (NDR) has since 1996 longi-
tudinally recorded medical outcomes e.g. risk factors, comorbidities, and covers
the majority (80%) of Swedish diabetes patients. In addition patient reported values
were collected alongside the registry in a questionnaire. Our purpose was to eval-
uate a method for measuring patient reported abilities and ratings of quality in
health care and evaluating them together with outcomes extracted from the NDR.
METHODS:A questionnaire was developed to measure if diabetes care is percieved
as patient focused and efficient, through questions on self management ability,
worries, ability to carry out daily acitivites, and perception of service, access and
involvement. The questionnaire was issued to 4,760 patients, 2,916 responded.
Registry data on risk factors (HbA1c, blood pressure, cholesterol) were extracted for
each patient and connected to the questionnaire. Item Response Theory (IRT) was
used to estimate patient abilities and patient ratings of quality in health care (IRT
scores) from the response patterns. For each patient, registry data and IRT scores
were used to derive an overall Malmquist approach output quantity index, a health
care related component and a patient ability component. The index is a measure-
ment of how efficiently the patient leads his or her life with diabetes and its care,
and provides a measure of the patient’s state of health in relation to the patient’s
situation. RESULTS: We obtained IRT scale models with good fit, satisfactory vali-
dated in another population. The IRT scores provide basis for patient evaluation in
a broader perspective than risk factors alone. The ability index component varies
more than the health care component.CONCLUSIONS:The questionnaire provides
estimates of abilities and ratings of quality. Our approach allows estimating patient
benefit and health care production using combined registry and patient reported
data, the procedure probably easier for patients than methods like time trade-off.
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OBJECTIVES: liraglutide and exenatide are the two known approved GLP-1 ana-
logue drug in the management of diabetes, a network meta-analysis was per-
formed to get a more robust evidence on the efficacy of liraglutide compared to
exenatide in achieving HbA1c  7.0% in more diabetic patient. METHODS: Elec-
tronic database was browsed for available material on the proposed subject until
May 2012, the inclusion criteria were phase 3 randomise controlled trials in diabe-
tes type 2 patients. The software ADDIS 1.14 (Aggregate Data Drug Information
System) was used to perform the network meta-analysis of liraglutide, exenatide
and insulin glargin. RESULTS: Node-splitting analyses showed that were no rele-
vant inconsistency in the evidence. A consistency model was used to draw conclu-
sion about the relative effect of the three treatments. The relative risk (RR) of
liraglutide compared to exenatide is 1.28 (0.57, 2.82), RR of liraglutide compared to
insulin glargine is 1.72 (0.70, 4.37) and the RR of exenatide compared to insulin
glargine is 1.35 (0.66, 2.76). A vague prior for the study specific baseline () and the
treatment effect coefficients () are   N (0, 3.563E-3) and   N (0, 3.563E-3)
respectively. The rank probability of the three drugs ranked liraglutide first, ex-
enatide second and insulin glargine as the last in rank of the best treatments.
CONCLUSIONS: Liraglutide is still effective in maintaining the HbA1c  7.0% in
more diabetes patients compared to exenatide and insulin glargine however ex-
enatide once weekly seems to be more convenient to administer and has a cost
advantage compared to liraglutide once daily dose. Liraglutide dose may need to be
modified to once weekly or once monthly dose to me more effective in the man-
agement of diabetes type 2.
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OBJECTIVES: Planning and designing patient registries requires significant re-
search to determine the type and amount of data to collect, identifying recruitment
sites, understanding the impact of study criteria on sample size, and estimating
patient retention. Our objective was to test the utility of a new tool for answering
these questions in a timely and cost-efficient manner, and to examine how claims
data can be leveraged to plan registry design. METHODS: We used an online inter-
active data analysis tool, MarketScan®Treatment Pathways, to explore the character-
istics and health care utilization patterns in a sample of cancer patients with pain.
Patients newly diagnosed with prevalent cancers that are highly associated with
pain such as multiple myeloma, colorectal, lung, prostate, or breast cancer were
included, if they had at least 2 ICD-9 codes for one of the cancers on different days
within 60 days of each other. A 6-month pre-period without any cancer diagnosis
was used to identify new cancer patients. RESULTS: Of the 365,980 cancer patients
meeting the entry criteria, 54% had an ICD-9 code for pain-related diagnosis. The
median and mean number of days from cancer to pain diagnosis was 113 and 192
days, respectively. Only 3% had a co-morbidity that would exclude participation in
the registry. Nearly 64% patients had an outpatient office visit within 30-days, of
them, 68% had a subsequent visit in the following 30-days. Patient diagnoses,
medications and procedures were described for the 60-day period following cancer
pain diagnosis. The full analysis took 6 hours including all iterations on study
criteria, and outputting descriptive data on patient demographic and clinical
characteristics. CONCLUSIONS: Using MarketScan®Treatment Pathways, we tested
sample selection criteria and health care utilization in a fraction of time than
typical database analyses. These data answered critical questions in the study
design for a planned cancer pain registry in a timely and cost-efficient way.
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OBJECTIVES: A systematic literature review (SLR) is a well-established tool for
identifying and assimilating existing evidence or identifying gaps that need to be
filled by new research. Although SLRs are widely used in the drug reimbursement
sphere, there are many challenges in maximizing its value and in communicating
project objectives with a vendor. The objective of this study is to outline the deliv-
erables of a SLR, and examine the optimal methodology in extracting maximum
value from a SLR review by exploring important caveats and pitfalls of two hypo-
thetical case studies. METHODS: Two hypothetical case studies are used to outline
the process and the pitfalls of a SLR project and the relationship between industry
and vendor. Feedback was elicited from consultants and industry in order to iden-
tify expectations and advice for a successful systematic literature review.
RESULTS: The analysis found that in depth discussion during the protocol phase of
the SLR is crucial to the success of the project. A successful protocol will incorpo-
rate: key questions that are focused and specific, scoping to outline the search
strategy, and address the purpose of the review in terms of a product’s value story
(ie. a SLR for inclusion in a GVD), or evidence development. The analysis found that
some challenges include too much or too little literature, which can be due to a very
broad or narrow research question, challenges that arise due to expectations for
certain data, and addressing gaps in the literature. Several suggestions on over-
coming these challenges and caveats of the methodology are explored through the
hypothetical case studies. CONCLUSIONS: The authors found that communication
and a focused question were the most helpful in yielding successful literature
reviews. Furthermore, detailed discussion at the protocol stage helped to avoid
pitfalls at later points in SLR development. The authors provide a list of pitfalls and
remedies that may help when considering SLRs.
RESEARCH ON METHODS - Modeling Methods
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OBJECTIVES: In the absence of long-term randomized clinical trials (RCTs) on the
effectiveness of pharmacological treatment for primary cardiovascular disease
(CVD) prevention, risk prediction models are used to project changes in CVD inci-
dence due to changes on risk factor levels observed in short-term RCTs. This study
aims to summarize the literature on the application of these CVD risk models in
pharmacoeconomic studies for primary CVD prevention interventions in high in-
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